This company listing is no longer active
Genocea Biosciences (GNCA.Q) Stock Overview
Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer immunotherapies. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
GNCA.Q Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Genocea Biosciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.0001 |
| 52 Week High | US$0.099 |
| 52 Week Low | US$0.0001 |
| Beta | 2.07 |
| 1 Month Change | 0% |
| 3 Month Change | -66.67% |
| 1 Year Change | -99.84% |
| 3 Year Change | -100.00% |
| 5 Year Change | -100.00% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Here's Why Shareholders May Want To Be Cautious With Increasing Genocea Biosciences, Inc.'s (NASDAQ:GNCA) CEO Pay Packet
Jun 17
What Type Of Returns Would Genocea Biosciences'(NASDAQ:GNCA) Shareholders Have Earned If They Purchased Their SharesFive Years Ago?
Feb 18How Much Of Genocea Biosciences, Inc. (NASDAQ:GNCA) Do Institutions Own?
Jan 14
Shareholder Returns
| GNCA.Q | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | -1.0% | -0.3% |
| 1Y | -99.8% | 26.8% | 15.3% |
Return vs Industry: GNCA.Q underperformed the US Biotechs industry which returned -3.5% over the past year.
Return vs Market: GNCA.Q underperformed the US Market which returned 15.2% over the past year.
Price Volatility
| GNCA.Q volatility | |
|---|---|
| GNCA.Q Average Weekly Movement | 1,251.8% |
| Biotechs Industry Average Movement | 11.2% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: GNCA.Q's share price has been volatile over the past 3 months.
Volatility Over Time: GNCA.Q's weekly volatility has increased from 816% to 1252% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 74 | Chip Clark | www.genocea.com |
Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor. Its products include GEN-011, an adoptive T cell therapy, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and GEN-009, a neoantigen vaccine candidate, which is in Phase 1/2a clinical trials that delivers adjuvanted synthetic long peptides spanning ATLAS-identified anti-tumor neoantigens.
Genocea Biosciences, Inc. Fundamentals Summary
| GNCA.Q fundamental statistics | |
|---|---|
| Market cap | US$5.88k |
| Earnings (TTM) | -US$37.19m |
| Revenue (TTM) | US$1.91m |
Is GNCA.Q overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GNCA.Q income statement (TTM) | |
|---|---|
| Revenue | US$1.91m |
| Cost of Revenue | US$0 |
| Gross Profit | US$1.91m |
| Other Expenses | US$39.10m |
| Earnings | -US$37.19m |
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.63 |
| Gross Margin | 100.00% |
| Net Profit Margin | -1,946.15% |
| Debt/Equity Ratio | 61.7% |
How did GNCA.Q perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/05/23 04:06 |
| End of Day Share Price | 2023/05/23 00:00 |
| Earnings | 2022/03/31 |
| Annual Earnings | 2021/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Genocea Biosciences, Inc. is covered by 9 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Michael Ulz | Baird |
| Mara Goldstein | Cantor Fitzgerald & Co. |
| Joseph Pantginis | H.C. Wainwright & Co. |